group researches the bio-pharma and related health industries, both in India and abroad.
Such studies, both
quantitatve and qualitative, should prove useful to policy making that is
geared to supporting an innovative industry.
In addition we have a series of general articles in
Current Science entitled 'Bio-business in brief'. These articles
highlight different aspects of drug discovery and development, including institutional arrangements, that are possibly of interest to
scientists and policy researchers. We hope that they will contribute to a debate that is vital to producing a knowledge
driven industry, itself important to ensure a healthier India.
Jaroslawski, S. and Saberwal, G.
Case studies of innovative medical device companies from India: Barriers and enablers to development.
BMC Health Services Research (in press)
Kumari, S. and Saberwal, G.
maintenence by Indian pharma and bio-pharma companies.
Asian Biotechnology Development Review (in press)
Giving voice to India's entrepreneurs.
Nature Biotechnology, 31, 104-107 (2013)
Marimuthu, G., Kumari, S.,
Kandasamy, M., Raghunathan, S. and Saberwal, G.
Patents protecting biologics or small molecule drugs are usually
Nature Biotechnology, 30, 50-53 (2012)
Soby, S, Sebastian, T.E. and
US patent holdings of Indian non-corporate entities.
Asian Biotechnology Development Review, 14, 21-33 (2012)
Soby, S., Kandasamy, M. and
Work outsourced to Indian biotech and pharma companies is not yet
Current Science, 102, 401-404 (2012)
Sebastian, T.E., Pattnayak,
J.P., Soby, S and Saberwal, G.
Patent holdings of Indian pharmaceutical and biotechnology companies in
international markets of different sizes.
Asian Biotechnology Development Review, 13, 17-37 (2011)
Seeding a skilled workforce.
Sebastian, T.E., Chandra Bindu,
Y. and Saberwal, G.
Patent holdings of US biotherapeutic companies in major markets.
14, 442-445 (2009)
Chandra Bindu, Y. , Mehdiratta, R. and Saberwal, G.
The US patent holdings of homegrown Indian biotech and pharma
Science, 96, 252-259 (2009)
Mehdiratta, R. and Saberwal, G.
How many patents does a bio-therapeutics company need?
Biotechnology, 26, 763-766 (2008)
New pharma-biotech company formation in India
24, 499-501 (2006)
SERIES OF ARTICLES IN CURRENT SCIENCE
Venkatachalam, S. and Saberwal, G
Bio-business in brief: A case for new drugs at generic prices from India
Science, 102, 1375-1381 (2012)
Translating academic discoveries
Science, 103, 767-769 (2012)
Bio-business in brief: A bit about technology transfer
Science, 99, 177-180 (2010)
Bio-business in brief: The debate over biosimilars
Science, 98, 1575-1578 (2010)
Bio-business in brief: The paradox of being a drug company
Devaguptapu, S, Mehdiratta, R
and Saberwal, G
Bio-business in brief: The case of Cytokinetics Inc.
Mehdiratta, R, Parida, D
K and Saberwal, G
Bio-business in brief: The challenges of clinical trials
Mehdiratta, R and Saberwal, G
Bio-business in brief: Many a monoclonal.
93, 789-796 (2007)
Mehdiratta, R and Saberwal, G
Bio-business in brief: The case of conotoxins.
92, 39-45 (2007)
PERSPECTIVES AND OTHER
Caring for a severely disabled person.
Kapoor, M. and Saberwal, G
The new crossroads
Biotech News, 5, 143-145 (2010).
Drug development in India: What does the future look like?
Contemporary Perspectives: History and Sociology of South Asia,
Ed. N Tyabji, 3, 293-309
A long march
News, IV, 68-69 & 75 (2009)
Biotechnology Incubation in India. In Business incubation:
Initiatives in India Ed. R. K. Lagu, brought out by NSTEDB, DST
We have received generous
funding from the Wadhwani Foundation and the Institut Merieux to
support our research and